跳转至内容
Merck
CN

C3275

Cytodex® 3微载体珠

>175 μm particle size (spherical), in 0.9% NaCl solution

登录 查看组织和合同定价。

选择尺寸


关于此项目

化学文摘社编号:
UNSPSC Code:
41121800
NACRES:
NB.22
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Cytodex® 3微载体珠, >175 μm particle size (spherical), in 0.9% NaCl solution

material

dextran beads

sterility

non-sterile

particle size

>175 μm (spherical)

density

1.04 g/cm3 at 25 °C

正在寻找类似产品? 访问 产品对比指南

Application

Cytodex™3微载体珠适用于:
  • 细胞的分离、运输和储存
  • 体外难培养的细胞,特别是具有上皮形态、敏感、分化或铺板效率低的细胞(例如内分泌细胞、肝细胞)
  • 病毒、细胞和重组细胞产品(如激素、核酸、酶、干扰素)的大规模生产 
对于在培养体系中通常难以生长的细胞(特别是上皮来源的细胞)。

Features and Benefits

  • 专为培养原代细胞或具有上皮样形态的细胞而设计,特别是铺板效率低的细胞或通常难以生长的分化或敏感细胞,例如肝细胞、内分泌细胞。
  • 微孔基质表面有一层酸变性猪胶原蛋白(明胶)。
  • 旨在产生具有最高活力的收获细胞。
  • 透明,便于对附着的细胞进行显微镜检查。

General description

体外难培养细胞的首选微载体。

微载体培养是一种使贴壁依赖性细胞的高产培养成为可能的实用技术。Cytodex是专门为培养各种动物细胞而开发的,培养量从几毫升到6000多升不等。在简单的悬浮培养系统中使用Cytodex可得到每毫升数百万个细胞的产量。

通过将一层薄薄的变性胶原蛋白与交联葡聚糖基质化学偶联而形成,这是体外难培养细胞的首选微载体,特别是具有上皮样形态的细胞。
表面包被变性猪皮胶原的葡聚糖珠。

Preparation Note

使用前,将微载体珠在PBS(50mL/g)中溶胀,并在120℃下高压灭菌。

Legal Information

Cytodex is a registered trademark of Cytiva

存储类别

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

David K Giles et al.
Microbes and infection, 10(14-15), 1494-1503 (2008-10-04)
Confinement of the obligate intracellular bacterium Chlamydia trachomatis to a membrane-bound vacuole, termed an inclusion, within infected epithelial cells neither prevents secretion of chlamydial antigens into the host cytosol nor protects chlamydiae from innate immune detection. However, the details leading
Kun Ding et al.
mAbs, 9(2), 269-284 (2016-12-09)
Exudative age-related macular degeneration (AMD) is the most common cause of moderate and severe vision loss in developed countries. Intraocular injections of vascular endothelial growth factor (VEGF or VEGF-A)-neutralizing proteins provide substantial benefit, but frequent, long-term injections are needed. In
Huanjiao Jenny Zhou et al.
Nature communications, 9(1), 3303-3303 (2018-08-19)
Regulation of VEGFR2 represents an important mechanism for the control of angiogenesis. VEGFR2 activity can be regulated by post-translational modifications such as ubiquitination and acetylation. However, whether VEGFR2 can be regulated by SUMOylation has not been investigated. Here we show
Jian Guang Xu et al.
Stem cell research & therapy, 8(1), 10-10 (2017-01-25)
Adequate vascularization is crucial for supplying nutrition and discharging metabolic waste in freshly transplanted tissue-engineered constructs. Obtaining the appropriate building blocks for vascular tissue engineering (i.e. endothelial and mural cells) is a challenging task for tissue neovascularization. Hence, we investigated
George Haddad et al.
Journal of the American Society of Nephrology : JASN, 32(2), 323-341 (2021-01-23)
Renal ischemia-reperfusion (I/R) injury is a major cause of AKI. Noncoding RNAs are intricately involved in the pathophysiology of this form of AKI. Transcription of hypoxia-induced, long noncoding RNA H19, which shows high embryonic expression and is silenced in adults

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持